Device makers, like pharmaceutical manufacturers, have long recognized that their success depends upon making their products known to physicians who will prescribe or recommend the use of their particular product.
In addition to their ability to influence current product use, physicians also are in the best position to conduct or oversee research that may expand future market share, including identifying additional clinical uses or adaptations for a product — some of which may not yet be approved by the U.S. Food and Drug Administration (FDA).
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc. This appeared in both Health Law360 and Competition Law360.
Author(s)
Related Insights
July 9, 2025
Foley Viewpoints
SEC and CFTC Extend Form PF Compliance Date Again
On June 11, 2025 the Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) again extended the…
July 9, 2025
Foley Viewpoints
Trump Accounts: The New Child Savings Account Established Under the One Big Beautiful Bill Act
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBA). The OBBA established a new type of tax-advantaged…
July 9, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…